Skip to main content
. 2022 Jan;10(1):67–77. doi: 10.22038/ABJS.2021.53750.2676

Table 2.

Incidence (per million person-years) of Primary Soft Tissue Sarcomas by Sex and Histologic Subtype, Iran (2009-2014)

Histologic Subtype Sex n Crude Rate ASR* 95% CI SRR 95% CI
Total Both sexes 2593 5.73 6.34 6.09-6.59
Male 1476 6.45 7.19 6.82-7.57 1.31** 1.21-1.42
Female 1117 4.99 5.47 5.15-5.80
Paragangliomas and Glomous Tumors Both sexes 1 <0.01 <0.01 -----
Male 1 <0.01 0.01 ----- ----- -----
Female 0 <0.01 <0.01 -----
Glomangiosarcoma Both sexes 1 <0.01 <0.01 -----
Male 1 <0.01 0.01 ----- ----- -----
Female 0 <0.01 <0.01 -----
Soft Tissue Sarcomas, NOS Both sexes 840 1.86 2.08 1.94-2.23
Male 475 2.08 2.35 2.14-2.57 1.30** 1.13-1.49
Female 365 1.63 1.81 1.62-2.00
Mesenchymal tumor Both sexes 318 0.70 0.81 0.71-0.90
Male 174 0.76 0.88 0.75-1.02 1.21 0.96-1.52
Female 144 0.64 0.73 0.61-0.85
Spindle cell sarcoma Both sexes 316 0.70 0.78 0.69-0.86
Male 190 0.83 0.94 0.80-1.07 1.53** 1.21-1.92
Female 126 0.56 0.61 0.50-0.72
Giant cell sarcoma/pleomorphic cell sarcoma Both sexes 113 0.25 0.30 0.24-0.35
Male 60 0.26 0.32 0.24-0.40 1.18 0.18-1.72
Female 53 0.24 0.27 0.20-0.34
Small cell sarcoma/round cell sarcoma Both sexes 17 0.04 0.04 0.02-0.06
Male 10 0.04 0.05 0.02-0.08 1.37 0.51-3.73
Female 7 0.03 0.03 0.01-0.06
Epithelioid sarcoma Both sexes 38 0.08 0.08 0.05-0.11
Male 23 0.10 0.09 0.05-0.13 1.33 0.69-2.56
Female 15 0.07 0.07 0.03-0.10
Undifferentiated sarcoma Both sexes 20 0.04 0.05 0.02-0.07
Male 10 0.04 0.05 0.02-0.08 0.86 0.35-2.12
Female 10 0.04 0.05 0.02-0.09
Desmoplastic round cell tumor Both sexes 18 0.04 0.04 0.02-0.06
Male 8 0.03 0.03 0.01-0.06 0.79 0.30-2.05
Female 10 0.04 0.04 0.02-0.07
Fibromatous Sarcomas Both sexes 486 1.07 1.23 1.12-1.35
Male 274 1.20 1.38 1.22-1.55 1.28** 1.07-1.54
Female 212 0.95 1.08 0.93-1.23
Fibrosarcoma Both sexes 114 0.25 0.26 0.21-0.31
Male 61 0.27 0.29 0.21-0.36 1.20 0.82-1.75
Female 53 0.24 0.24 0.17-0.31
Fibromyxosarcoma Both sexes 24 0.05 0.06 0.03-0.08
Male 8 0.03 0.04 0.01-0.08 0.61 0.26-1.40
Female 16 0.07 0.07 0.04-0.11
Infantile/congenital fibrosarcoma Both sexes 6 0.01 0.01 0.00-0.03
Male 3 0.01 0.01 0.00-0.03 ----- -----
Female 3 0.01 0.01 0.00-0.03
Solitary fibrous tumor Both sexes 3 0.01 0.01 0.00-0.02
Male 1 <0.01 <0.01 0.00-0.01 ----- -----
Female 2 0.01 0.01 0.00-0.03
Fibrous histiocytoma/fibroxanthoma Both sexes 297 0.66 0.80 0.71-0.89
Male 177 0.77 0.93 0.79-1.08 1.42** 1.12-1.79
Female 120 0.54 0.66 0.54-0.78
Dermatofibrosarcoma Both sexes 42 0.09 0.09 0.06-0.12
Male 24 0.10 0.10 0.06-0.14 1.26 0.68-2.34
Female 18 0.08 0.08 0.04-0.12
Myxomatous Sarcomas Both sexes 5 0.01 0.01 0.00-0.03
Male 3 0.01 0.02 0.00-0.04 ----- -----
Female 2 0.01 0.01 0.00-0.02
Myxosarcom Both sexes 5 0.01 0.01 0.00-0.03
Male 3 0.01 0.02 0.00-0.04 ----- -----
Female 2 0.01 0.01 0.00-0.02
Lipomatous Sarcomas Both sexes 370 0.82 0.92 0.83-1.02
Male 203 0.89 1.01 0.87-1.15 1.21 0.98-1.49
Female 167 0.75 0.83 0.70-0.96
Liposarcoma/fibroliposarcoma Both sexes 77 0.17 0.19 0.15-0.24
Male 39 0.17 0.20 0.14-0.27 1.09 0.69-1.72
Female 38 0.17 0.18 0.12-0.24
Liposarcoma, well differentiated Both sexes 50 0.11 0.13 0.09-0.17
Male 24 0.10 0.12 0.07-0.17 0.92 0.52-1.63
Female 26 0.12 0.13 0.08-0.19
Myxoid Liposarcoma Both sexes 163 0.36 0.39 0.33-0.45
Male 93 0.41 0.44 0.35-0.53 1.28 0.93-1.76
Female 70 0.31 0.34 0.26-0.42
Round cell liposarcoma Both sexes 19 0.04 0.04 0.02-0.06
Male 12 0.05 0.06 0.02-0.09 1.86 0.72-4.81
Female 7 0.03 0.03 0.01-0.05
Pleomorphic liposarcoma Both sexes 40 0.09 0.11 0.08-0.15
Male 22 0.10 0.12 0.07-0.18 1.23 0.68-2.42
Female 18 0.08 0.10 0.05-0.14
Mixed liposarcoma Both sexes 11 0.02 0.03 0.01-0.04
Male 8 0.03 0.04 0.01-0.06 2.30 0.64-8.23
Female 3 0.01 0.02 0.00-0.04
Fibromyxosarcoma Both sexes 24 0.05 0.06 0.03-0.08
Male 8 0.03 0.04 0.01-0.08 0.61 0.26-1.40
Female 16 0.07 0.07 0.04-0.11
Infantile/congenital fibrosarcoma Both sexes 6 0.01 0.01 0.00-0.03
Male 3 0.01 0.01 0.00-0.03 ----- -----
Female 3 0.01 0.01 0.00-0.03
Solitary fibrous tumor Both sexes 3 0.01 0.01 0.00-0.02
Male 1 <0.01 <0.01 0.00-0.01 ----- -----
Female 2 0.01 0.01 0.00-0.03
Fibrous histiocytoma/fibroxanthoma Both sexes 297 0.66 0.80 0.71-0.89
Male 177 0.77 0.93 0.79-1.08 1.42** 1.12-1.79
Female 120 0.54 0.66 0.54-0.78
Dermatofibrosarcoma Both sexes 42 0.09 0.09 0.06-0.12
Male 24 0.10 0.10 0.06-0.14 1.26 0.68-2.34
Female 18 0.08 0.08 0.04-0.12
Myxomatous Sarcomas Both sexes 5 0.01 0.01 0.00-0.03
Male 3 0.01 0.02 0.00-0.04 ----- -----
Female 2 0.01 0.01 0.00-0.02
Myxosarcom Both sexes 5 0.01 0.01 0.00-0.03
Male 3 0.01 0.02 0.00-0.04 ----- -----
Female 2 0.01 0.01 0.00-0.02
Lipomatous Sarcomas Both sexes 370 0.82 0.92 0.83-1.02
Male 203 0.89 1.01 0.87-1.15 1.21 0.98-1.49
Female 167 0.75 0.83 0.70-0.96
Liposarcoma/fibroliposarcoma Both sexes 77 0.17 0.19 0.15-0.24
Male 39 0.17 0.20 0.14-0.27 1.09 0.69-1.72
Female 38 0.17 0.18 0.12-0.24
Liposarcoma, well differentiated Both sexes 50 0.11 0.13 0.09-0.17
Male 24 0.10 0.12 0.07-0.17 0.92 0.52-1.63
Female 26 0.12 0.13 0.08-0.19
Myxoid Liposarcoma Both sexes 163 0.36 0.39 0.33-0.45
Male 93 0.41 0.44 0.35-0.53 1.28 0.93-1.76
Female 70 0.31 0.34 0.26-0.42
Round cell liposarcoma Both sexes 19 0.04 0.04 0.02-0.06
Male 12 0.05 0.06 0.02-0.09 1.86 0.72-4.81
Female 7 0.03 0.03 0.01-0.05
Pleomorphic liposarcoma Both sexes 40 0.09 0.11 0.08-0.15
Male 22 0.10 0.12 0.07-0.18 1.23 0.68-2.42
Female 18 0.08 0.10 0.05-0.14
Mixed liposarcoma Both sexes 11 0.02 0.03 0.01-0.04
Male 8 0.03 0.04 0.01-0.06 2.30 0.64-8.23
Female 3 0.01 0.02 0.00-0.04
Carcinosarcoma Both sexes 1 <0.01 <0.01 ------
Male 0 <0.01 <0.01 ------ ------ ------
Female 1 <0.01 <0.01 ------
Mixed mesenchymal sarcoma Both sexes 6 0.01 0.02 0.00-0.03
Male 4 0.02 0.02 0.00-0.04 ------ ------
Female 2 0.01 0.01 0.00-0.02
Synovial Like Sarcomas Both sexes 353 0.78 0.79 0.71-0.88
Male 205 0.90 0.92 0.79-1.06 1.40** 1.13-1.74
Female 148 0.66 0.66 0.55-0.77
Synovial sarcoma, NOS Both sexes 184 0.41 0.42 0.35-0.48
Male 106 0.45 0.48 0.39-0.58 1.38** 1.02-1.86
Female 78 0.35 0.35 0.27-0.43
Synovial sarcoma, spindle cell Both sexes 79 0.17 0.17 0.13-0.21
Male 49 0.21 0.22 0.16-0.29 1.72** 1.08-2.75
Female 30 0.13 0.13 0.08-0.18
Synovial sarcoma, epithelioid cell Both sexes 4 0.01 0.01 0.00-0.02
Male 1 <0.01 <0.01 0.00-0.01 ------ ------
Female 3 0.01 0.01 0.00-0.03
Synovial sarcoma, biphasic Both sexes 60 0.13 0.13 0.10-0.16
Male 33 0.14 0.14 0.09-0.19 1.19 0.71-2.01
Female 27 0.12 0.12 0.07-0.16
Clear cell sarcoma of tendons and aponeuroses, melanoma Both sexes 26 0.06 0.06 0.04-0.08
Male 16 0.07 0.07 0.04-0.11 1.51 0.67-3.39
Female 10 0.04 0.05 0.02-0.08
Blood Vessels Sarcomas Both sexes 61 0.13 0.16 0.12-0.21
Male 38 0.17 0.21 0.14-0.28 1.72** 1.02-2.91
Female 23 0.10 0.12 0.07-0.17
Haemangiosarcoma Both sexes 22 0.05 0.06 0.03-0.09
Male 8 0.03 0.04 0.01-0.08 0.57 0.24-1.38
Female 14 0.06 0.08 0.04-0.12
Hemangioendothelial sarcoma Both sexes 3 0.01 0.01 0.00-0.02
Male 2 0.01 0.01 0.00-0.02 ------ ------
Female 1 0.00 <0.001 ------
Kaposi sarcoma Both sexes 29 0.06 0.08 0.05-0.11
Male 24 0.10 0.13 0.08-0.19 5.32** 2.15-13.15
Female 5 0.02 0.03 0.00-0.05
Malignant Haemangiopericytoma Both sexes 7 0.02 0.02 0.00-0.03
Male 4 0.02 0.02 0.00-0.04 1.43 0.31-6.60
Female 3 0.01 0.01 0.00-0.03
Lymphatic Vessels Sarcomas Both sexes 2 <0.001 0.01 0.00-0.01
Male 1 <0.001 0.01 0.00-0.02 ------ ------
Female 2 0.01 0.01 0.0-0.03
Lymphangiosarcoma Both sexes 2 <0.001 0.01 0.00-0.01
Male 1 <0.001 0.01 0.00-0.02 ------ ------
Female 2 0.01 0.01 0.0-0.03
Giant Cell Tumors-Malignant Both sexes 44 0.10 0.10 0.07-0.14
Male 23 0.10 0.11 0.06-0.15 1.03 0.56-1.88
Female 21 0.09 0.10 0.06-0.15
Malignant giant cell tumor of soft parts Both sexes 19 0.04 0.04 0.02-0.06
Male 14 0.06 0.06 0.03-0.10 2.83** 1.04-7.72
Female 5 0.02 0.02 0.00-0.04
Malignant tenosynovial giant cell tumor Both sexes 25 0.06 0.06 0.04-0.09
Male 9 0.04 0.04 0.01-0.07 0.52 0.23-1.19
Female 16 0.07 0.08 0.04-0.12
Nerve Sheath Tumors-Malignant Both sexes 96 0.21 0.22 0.18-0.27
Male 66 0.29 0.30 0.22-0.37 2.09** 1.36-3.21
Female 30 0.13 0.14 0.09-0.20
Malignant peripheral nerve sheath tumor Both sexes 91 0.20 0.21 0.17-0.25
Male 63 0.28 0.28 0.21-0.36 2.10** 1.35-3.26
Female 28 0.13 0.14 0.08-0.19
malignant schwannoma, Neurilemmosarcoma Both sexes 3 0.01 0.01 0.00-0.02
Male 1 <0.001 <0.001 ------ ------ ------
Female 2 0.01 0.01 0.00-0.02
Malignant peripheral nerve sheath tumor Both sexes 2 <0.001 <0.001 ------
Male 2 0.01 0.01 0.00-0.02 ------ ------
Female 0 <0.001 <0.001 ------
Granular cell and Alveolar Soft Tissue Sarcoma Both sexes 21 0.05 0.04 0.02-0.06
Male 10 0.04 0.04 0.01-0.06 0.82 0.34-1.97
Female 11 0.05 0.05 0.02-0.08
Alveolar soft part sarcoma Both sexes 21 0.05 0.04 0.02-0.06
Male 10 0.04 0.04 0.01-0.06 0.82 0.34-1.97
Female 11 0.05 0.05 0.02-0.08
Ewing tumor and Askin tumor of soft tissue Both sexes 68 0.15 0.14 0.11-0.17
Male 42 0.18 0.17 0.12-0.22 1.44 0.88-2.35
Female 26 0.12 0.12 0.07-0.16

ASIR = age-standardized incidence rate, CI = confidence interval, NOS = not otherwise specified

SRR = male-to-female standardized incidence rate (ASIR) ratio

*ASRs were age-standardized to the new world health organizing (WHO) standard population

** Indicates statistical significance at the 0.05 level